TabletsClinical Overview
Cabozantinib Tablets (20mg, 40mg, 60mg) is an oral multi-tyrosine kinase inhibitor targeting MET, VEGFR-1/2/3, RET, AXL, KIT, and TIE-2 on the PMBI formulary. Simultaneous inhibition of MET and AXL overcomes resistance pathways commonly triggered by VEGF-only blockade. Indicated for advanced renal cell carcinoma (RCC) following prior anti-angiogenic therapy, hepatocellular carcinoma (HCC) previously treated with sorafenib, and progressive medullary thyroid cancer.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally 60 mg once daily on an EMPTY STOMACH: at least 1 hour before or 2 hours after food with a glass of water. Swallow whole.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Diarrhea, fatigue, hand-foot syndrome, hypertension, weight loss, nausea, dysgeusia, stomatitis. Rare/Severe: Gastrointestinal perforation and fistulas, severe hemorrhage, arterial thromboembolic events, and posterior reversible encephalopathy syndrome (PRES).
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Black Box Warning: Gastrointestinal perforations, fistulas, and severe hemorrhage. Discontinue permanently if perforation or severe fistula develops. Stop treatment at least 28 days prior to scheduled elective surgery. Monitor for severe hypertension.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, oncological diagnosis, or chemotherapy protocol guidance. Cancer therapies require specialized administration under the direct supervision of a registered medical oncologist in an accredited healthcare facility.
Cabozantinib Tablets 40 mg
Cabozantinib Tablets (20mg, 40mg, 60mg) is an oral multi-tyrosine kinase inhibitor targeting MET, VEGFR-1/2/3, RET, AXL, KIT, and TIE-2 on the PMBI formulary. Simultaneous inhibition of MET and AXL overcomes resistance pathways commonly triggered by VEGF-only blockade. Indicated for advanced renal cell carcinoma (RCC) following prior anti-angiogenic therapy, hepatocellular carcinoma (HCC) previously treated with sorafenib, and progressive medullary thyroid cancer.
Cabozantinib Tablets 60 mg
Cabozantinib Tablets (20mg, 40mg, 60mg) is an oral multi-tyrosine kinase inhibitor targeting MET, VEGFR-1/2/3, RET, AXL, KIT, and TIE-2 on the PMBI formulary. Simultaneous inhibition of MET and AXL overcomes resistance pathways commonly triggered by VEGF-only blockade. Indicated for advanced renal cell carcinoma (RCC) following prior anti-angiogenic therapy, hepatocellular carcinoma (HCC) previously treated with sorafenib, and progressive medullary thyroid cancer.